TR201309037A2 - Dapoksetin ve bir pde5 inhibitörü içeren yeni efervesan saşe formülasyonları. - Google Patents

Dapoksetin ve bir pde5 inhibitörü içeren yeni efervesan saşe formülasyonları.

Info

Publication number
TR201309037A2
TR201309037A2 TR2013/09037A TR201309037A TR201309037A2 TR 201309037 A2 TR201309037 A2 TR 201309037A2 TR 2013/09037 A TR2013/09037 A TR 2013/09037A TR 201309037 A TR201309037 A TR 201309037A TR 201309037 A2 TR201309037 A2 TR 201309037A2
Authority
TR
Turkey
Prior art keywords
dapoxetine
pde5 inhibitor
sachet formulations
effervescent sachet
novel
Prior art date
Application number
TR2013/09037A
Other languages
English (en)
Inventor
Türkyilmaz Ali̇
Yelken Gülay
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to PCT/TR2013/000273 priority Critical patent/WO2014027982A2/en
Priority to US14/421,333 priority patent/US20150231092A1/en
Priority to EP13180731.5A priority patent/EP2700398A1/en
Publication of TR201309037A2 publication Critical patent/TR201309037A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş, dapoksetin veya onun farmasötik olarak kabul edilebilir bir tuzunun bir Fosfodiesteraz Tip 5 inhibitörü ve kombinasyonunu içeren yeni efervesan saşe formülasyonları ile ilgilidir. Buluş ayrıca bu gibi bir formülü hazırlamak için bir proses ve bunun erektil disfonksiyon tedavisinde kullanımıyla da ilgilidir.
TR2013/09037A 2012-08-17 2013-07-25 Dapoksetin ve bir pde5 inhibitörü içeren yeni efervesan saşe formülasyonları. TR201309037A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/TR2013/000273 WO2014027982A2 (en) 2012-08-17 2013-08-15 Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
US14/421,333 US20150231092A1 (en) 2012-08-17 2013-08-15 Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
EP13180731.5A EP2700398A1 (en) 2012-08-17 2013-08-16 Effervescent Sachet Formulations of Dapoxetine and a Pde5 Inhibitor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
TR201209599 2012-08-17
TR201212488 2012-10-31
TR201212850 2012-11-07
TR201301536 2013-02-07
TR201301559 2013-02-08
TR201306476 2013-05-30

Publications (1)

Publication Number Publication Date
TR201309037A2 true TR201309037A2 (tr) 2014-03-21

Family

ID=48953341

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2013/09037A TR201309037A2 (tr) 2012-08-17 2013-07-25 Dapoksetin ve bir pde5 inhibitörü içeren yeni efervesan saşe formülasyonları.

Country Status (4)

Country Link
US (1) US20150196506A1 (tr)
EP (1) EP2698148A1 (tr)
TR (1) TR201309037A2 (tr)
WO (1) WO2014027978A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230210743A1 (en) * 2022-01-04 2023-07-06 Cao Group, Inc. Dithionite shelf-stable sweeteners
CN115645540A (zh) * 2022-12-22 2023-01-31 北京中科利华医药研究院有限公司 一种他达拉非喷雾剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85988A (en) 1987-04-09 1992-08-18 Lilly Co Eli 1-phenyl-3-naphthalenyloxy-propanamines,process for their preparation and pharmaceutical compositions containing them
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
CN101143145B (zh) * 2006-09-11 2011-11-09 黑龙江大学 他达拉非口香糖及制作方法和应用
EP2167048B1 (en) * 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
EP2316435A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine

Also Published As

Publication number Publication date
EP2698148A1 (en) 2014-02-19
WO2014027978A1 (en) 2014-02-20
US20150196506A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
CA2871471C (en) Dna-pk inhibitors
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA202091303A3 (ru) Композиция ингибитора jak для местного применения
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
NZ626618A (en) Hydroxamic acid derivatives and uses thereof
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
MY149705A (en) Pyridino-pyridinone derivatives, preparation therof, and therapeutic use thereof
PH12015502118A1 (en) Pyridin-4-yl derivatives
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
EA201390799A1 (ru) Триазолопиридины
EA201492069A1 (ru) Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10)
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
WO2014027981A3 (en) Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
PH12015500399A1 (en) Azaindolines
WO2015055898A3 (en) Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient
TR201309037A2 (tr) Dapoksetin ve bir pde5 inhibitörü içeren yeni efervesan saşe formülasyonları.
EP2578588A4 (en) NEW DERIVATIVES OF 1, 4 -DIAZEPINES, PDE-5 INHIBITORS
WO2014027982A3 (en) Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
MX2014014258A (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis.